A new trading day began on Monday, with Keros Therapeutics Inc (NASDAQ: KROS) stock price up 3.13% from the previous day of trading, before settling in for the closing price of $18.83. KROS’s price has ranged from $15.67 to $73.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -40.00% over the past five years. Meanwhile, its annual earnings per share averaged 0.03%. With a float of $30.96 million, this company’s outstanding shares have now reached $39.26 million.
Let’s look at the performance matrix of the company that is accounted for 136 employees. In terms of profitability, gross margin is -27.5%, operating margin of -31341.63%, and the pretax margin is -27890.94%.
Keros Therapeutics Inc (KROS) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Keros Therapeutics Inc is 23.56%, while institutional ownership is 79.02%. The most recent insider transaction that took place on Aug 13 ’24, was worth 11,002,500. In this transaction Director of this company sold 250,000 shares at a rate of $44.01, taking the stock ownership to the 119,522 shares. Before that another transaction happened on Aug 13 ’24, when Company’s Director sold 250,000 for $44.01, making the entire transaction worth $11,002,500. This insider now owns 119,522 shares in total.
Keros Therapeutics Inc (KROS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.80% during the next five years compared to -111.11% drop over the previous five years of trading.
Keros Therapeutics Inc (NASDAQ: KROS) Trading Performance Indicators
Here are Keros Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 19.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1210.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.21, a number that is poised to hit -1.36 in the next quarter and is forecasted to reach -5.21 in one year’s time.
Technical Analysis of Keros Therapeutics Inc (KROS)
Keros Therapeutics Inc (NASDAQ: KROS) saw its 5-day average volume 4.57 million, a positive change from its year-to-date volume of 0.46 million. As of the previous 9 days, the stock’s Stochastic %D was 5.68%. Additionally, its Average True Range was 6.38.
During the past 100 days, Keros Therapeutics Inc’s (KROS) raw stochastic average was set at 6.61%, which indicates a significant increase from 6.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 547.42% in the past 14 days, which was higher than the 214.15% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $58.33, while its 200-day Moving Average is $54.86. Nevertheless, the first resistance level for the watch stands at $20.02 in the near term. At $20.62, the stock is likely to face the second major resistance level. The third major resistance level sits at $21.59. If the price goes on to break the first support level at $18.45, it is likely to go to the next support level at $17.48. The third support level lies at $16.88 if the price breaches the second support level.
Keros Therapeutics Inc (NASDAQ: KROS) Key Stats
With a market capitalization of 786.65 million, the company has a total of 40,507K Shares Outstanding. Currently, annual sales are 150 K while annual income is -152,990 K. The company’s previous quarter sales were 390 K while its latest quarter income was -52,960 K.
